Tenet Healthcare (THC) Stock

The mean of analysts' price targets for Tenet (THC) points to a 30.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks.com users have recently been watching Tenet (THC) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

THC continues to experience strong demand for its services, which is expected to continue throughout the year.

Tenet Healthcare shares have been scorching-hot in 2024, up 115% and outperforming many of the Mag 7 members.

Tenet (THC) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Tenet Healthcare Corporation (NYSE:THC ) Q3 2024 Earnings Conference Call October 29, 2024 10:00 AM ET Company Participants Will McDowell – Vice President-Investor Relations Saum Sutaria – Chairman and Chief Executive Officer Sun Park – Executive Vice President and Chief Financial Officer Conference Call Participants Josh Raskin – Nephron Research Ben Hendrix – RBC Capital Markets A.J. Rice – UBS Stephen Baxter – Wells Fargo Ann Hynes – Mizuho Michael Ha – Baird Pito Chickering – Deutsche Bank Justin Lake – Wolfe Research Joanna Gajuk – Bank of America Whit Mayo – Leerink Partners Andrew Mok – Barclays Brian Tanquilut – Jefferies Matthew Gillmor – KeyBanc Capital Markets Sarah James – Cantor Fitzgerald John Ransom – Raymond James Jamie Perse – Goldman Sachs Operator Good morning, and welcome to Tenet Healthcare's Third Quarter 2024 Earnings Conference Call.

Although the revenue and EPS for Tenet (THC) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Tenet Healthcare (THC) came out with quarterly earnings of $2.93 per share, beating the Zacks Consensus Estimate of $2.33 per share. This compares to earnings of $1.44 per share a year ago.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.